Radioimmunetheranostics – An Emerging Approach in Personalized Oncology
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 392
Special Issue Editor
Special Issue Information
Dear Colleagues,
Monitoring the delivery success of therapies and the treatment response of cancers in real time is of high ethical and clinical need. Molecular targeting radiopharmaceuticals, with its proven ability to direct the clinical management of many cancers, are considered to a main future in personalized oncology. On the other hand, immune therapies are revolutionizing cancer therapy with manifesting themselves as treatments of choice for many cancers. This Special Issue is dedicated to presenting the current concepts and results of research combining those powerful approaches in the field of radioimmunetherapy. With a planned focus on—but not limited to—neuro-oncology, a disease class presenting particular high challenges for the development of effective treatments, this Special Issue will comprise different areas relevant for the development of radioimmuntheranostics including disease modeling, radiopharmaceutics and nanofunctionalization thereof, the engineering of cellular immunotherapies. Moreover, the potential of biosensors to resource-efficiently monitor the disease progression of theranostic interventions in a POCT environment will be presented.
Dr. Ulf D. Kahlert
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiopharmaceuticals
- immune therapy
- theranostics
- brain tumor
- biosensors
- personalized medicine
- stem cells
- disease modeling
- CAR-T
